×

Leadership Corporate Leaders

  • Novellus Systems, a supplier of equipment for making microchips, said Monday that its chief financial officer will resign around late February and join a private venture-backed company.

  • Student lender SLM -- better known as Sallie Mae -- said Friday that its executive chairman Albert Lord will take on the extra role of chief executive officer.

  • dendreon_logo_new2.jpg

    The biotech momentum players and the Dendreonites--or Dendreonians--are buzzing about the story we broke on "Power Lunch" Thursday that three members of Congress are asking the House Energy and Commerce Committee to hold a hearing about the Dendreon/Provenge saga. The shares spiked on very heavy volume.

  • Stanley O'Neal

    Merrill Lynch ousted Chairman and Chief Executive Stan O'Neal just days after reporting the biggest quarterly loss in the company's history, making him the highest-ranking casualty in the U.S. subprime mortgage crisis.

  • Cramer says it's already priced into the stock.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Goldman Sachs Chairman and Chief Executive Lloyd Blankfein is likely to get a 30 percent pay rise this year to about $70 million, despite the liquidity squeeze which has seen shares in the banking sector tumble, the Financial Times reported on its Web site.

  • underwater_67.jpg

    Last year one of our producers had the bright idea of assigning each of CNBC's beat reporters a story about seven predictions for their beat for 2007. So, now this year not only do we have to do the 8 for '08 thing for TV, but also for the blog.

  • wef_dimon_93.jpg

    In the spirit of Outlook '08, here are my predictions for 2008. We'll see how I did come this time next year. My personal favorite is number 7!!

  • The morning after the Merck annual business briefing, the analyst reviews are pouring in. For the most part, the ones that I've received at least, say it had a good beat. Only Sanford C. Bernstein's Tim Anderson says he can't dance to it. He titles a research note to clients, "Annual Business Review Uneventful--No Real Surprises, Positive Or Negative."

  • A quarter-point cut wasn't enough, he says. So what happens now?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • merck_logo.jpg

    I'm back at Merck HQ in central Jersey for the annual analyst meeting. And I must say that the reception--so far, at least--is much more hospitable and helpful than last year wen things were tense and got a little ugly. A new pr team is in place.

  • The Austrian running the world's largest food group talks about trust and the need to delegate in order for an organisation of Nestle's complexity to succeed. Peter Brabeck also hits back at critics of his decision to take the dual mandate of Chairman and CEO, whilst rebuffing journalists who write he's chosen the wrong candidate to succeed him as CEO.

  • Dow Jones, publisher of the Wall Street Journal, said Thursday that Chief Executive Richard Zannino will leave the company once its acquisition by News Corp is completed.

  • genentech_logo_1.jpg

    My inbox is flooded this morning with research notes from analysts in the wake of yesterday's FDA panel meeting on Genentech's Avastin for breast cancer. The advisory committee voted 5-4 against recommending approval of the drug for that use. The FDA usually follows the advice of its outside panels of experts, but in close votes like this one it's not unheard of for the agency to go the other way.

  • CEO Jim Cornelius

    Regular blog readers are well aware of my relentless pursuit of big CEO interviews. So, I wanted to give the backstory to a surprising CEO cancellation of a previously scheduled and confirmed interview today by Bristol-Myers Squibb. A few weeks ago, my producer Ruth and I got tentative confirmation from a Bristol spokesman that the relatively new CEO Jim Cornelius would finally do his first TV interview since taking over the company last year.

  • China and online advertisers will be the saviors of the advertising industry, according to Sir Martin Sorrell, CEO of advertising giant WPP. 

  • bristol_myers_squibb.jpg

    I don't know how they all got clustered together--maybe so many of the major pharmaceutical companies meet with Wall Street in early December so everyone can then take off on long vacations--but my hands are full with three big pharma events in as many days. Yesterday, Merck put out guidance.

  • C-suite confidence is at its lowest level since May of 2003, according to a new survey by Chief Executive Magazine.

  • Merrill Lynch's new Chief Executive John Thain has received about $2.6 million in restricted stock and nearly 43,000 options to replace shares he forfeited by leaving NYSE Euronext, according to U.S. regulatory filings.